engleski

ANTISTEATOTIC EFFECT OF LIRAGLUTIDE IS MEDIATED THROUGH ACSL1 and SREBP-1c SIGNALING PATHWAY IN A CELL CULTURE MODEL OF TAMOXIFEN-INDUCED STEATOSIS

Introduction: Nonalcoholic fatty liver disease (NAFLD) has become one of the global health problems. Drugs, such as tamoxifen, may trigger or exacerbate pre-existing NAFLD. The aim of our study was to establish a reliable cell culture model of tamoxifen-induced steatosis (TIS) and to investigate a possible antisteatotic effect of the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide in this model. Materials and methods: The cell culture model of drug-induced hepatic steatosis was established by incubating Huh7 cells, a human liver cell line expressing the GLP- 1 receptor, with 2 μM tamoxifen for 24 hours. Cells were co-treated with 5 nM to 20 nM liraglutide. Cell survival was measured by the erythrosin B staining exclusion assay, and changes in cell shape and the extent of hepatosteatosis were assessed by fluorescence microscopy with Oil- Red-O (ORO) and DAPI staining, respectively. The expression of various lipogenic genes and signals was assessed by RT-PCR. Results: Tamoxifen significantly decreased cell survival in the TIS model (p < 0, 05), and concurrent treatment with liraglutide had no significant effect. A 5-fold increase in lipid accumulation was observed by ORO staining in the TIS model (p < 0, 001), which was due to the significant increase in the number of lipid droplets. However, liraglutide reversed this effect and significantly decreased the number of lipid droplets (p < 0, 05). Liraglutide co- treatment significantly ameliorated the lipogenic ACSL1 and SREBP-1c gene expression signaling pathways, which were increased in the TIS model (p < 0, 001). Conclusions: Liraglutide ameliorates microsteatotic changes observed in TIS model by downregulation of ACSL1 and SREBP-1c gene pathways.

liraglutide ; tamoxifen ; non-alcoholic fatty liver disease ; Huh7 cell culture

nije evidentirano